The US Food and Drug Administration has approved a landmark eye drop that uses a combined dose of medication to restore ...

The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, making it the first approved dual-agent eye drop therapy for age-related vision decline. The ...

SAN DIEGO — An experimental combination of drugs can temporarily correct the vision of people with presbyopia, a new study shows. "With one drop in the morning, you don't need glasses all day," said ...

Review the side-effects of Carbachol as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Findings showed Brimochol PF significantly improved near vision compared with vehicle solution at all timepoints up to 8 hours (P .008). Topline data were announced from a phase 3 trial evaluating ...

A Prescription Drug User Fee Act target date of January 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brimochol ™ ...

Eye redness was not a commonly reported side effect in clinical trials of YUVEZZI. In BRIO I and BRIO II the reports of adverse events of ocular hyperemia (eye redness) were low. 1,2 In BRIO II, the ...

Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval (PDF) for Yuvezzi, a treatment for presbyopia, a common, age-related ...

To test whether carbachol can influence endothelial barrier dysfunction induced by tumor necrosis factor (TNF)-α and whether the alpha 7 nicotinic receptor can mediate this process. Rat cardiac ...

Activation of muscarinic receptors on the detrusor smooth muscle is followed by contraction, which involves both myosin light chain kinase (MLCK) and Rho kinase (ROCK). The aim of this study was to ...